Eric Armentani

Eric Armentani

Auto-generated profile, based on publicly available information

Eric Armentani

Bright Peak Therapeutics, Inc., Basel, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2018 in Nature
Verified
Journal Article
Closed access
PDF file
DLDaniela Latorre
Daniela Latorre
UKUlf Kallweit
Ulf Kallweit
EAEric Armentani
Eric Armentani
MFMathilde Foglierini
Mathilde Foglierini
FMFederico Mele
Federico Mele
FSFederica Sallusto
Federica Sallusto

1 August 2016 in Journal of Autoimmunity
Verified
Journal Article
Open access
ALAlice Laroni
Alice Laroni
EAEric Armentani
Eric Armentani
NRNicole Kerlero de Rosbo
Nicole Kerlero de Rosbo
FIFederico Ivaldi
Federico Ivaldi
EMEmanuela Marcenaro
Emanuela Marcenaro
AUAntonio Uccelli
Antonio Uccelli
Recent evidence has shown that CD56(bright) NK cells, a subset of NK cells abundant in lymph nodes, may have an immunoregulatory function. In multiple sclerosis (MS), expansion of CD56(bright) NK cells has been associated to successful response to different treatments and to remission of disease during pregnancy; how whether they exert immunoregulation in physiologic conditions and whether this is impaired in MS is not known. We dissected the immunoregulatory role of CD56(bright) NK cells function in healthy subjects (HS) and compared it with that of untreated MS subjects or patients with clinically isolated syndrome suggestive of MS (CIS). We found that CD56(bright) NK cells from HS acquire, upon inflammatory cues, the capability of suppressing autologous CD4+T cell proliferation through direct cytotoxicity requiring engagement of natural cytotoxicity receptors (NCRs) and secretion of granzyme B. CD56(bright) NK cells from patients with MS/CIS did not differ in frequency and share a similar phenotype but displayed a significantly lower ability to inhibit autologous T cell proliferation. This impairment was not related to deficient expression of NCRs or granzyme B by CD56(bright) NK cells, but to increased HLA-E expression on T cells from MS/CIS subjects, which could enhance the inhibitory effect mediated by NKG2A that is homogeneously expressed on CD56(bright) NK cells. The defect in controlling autologous T cells by CD56(bright) NK cells in MS/CIS might contribute to the excess of autoimmune response that is associated to disease development.

1 January 2017 in Immunology Letters
Verified
Journal Article
Closed access
IGIlaria Gandoglia
Ilaria Gandoglia
FIFederico Ivaldi
Federico Ivaldi
PCPaolo Carrega
Paolo Carrega
EAEric Armentani
Eric Armentani
GFGuido Ferlazzo
Guido Ferlazzo
ALAlice Laroni
Alice Laroni

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
JCJean-Philippe Carralot
Jean-Philippe Carralot
MRMatilde Arévalo Ruiz
Matilde Arévalo Ruiz
RTRobert Tam
Robert Tam
EAEric Armentani
Eric Armentani
VPVijaya R. Pattabiraman
Vijaya R. Pattabiraman
BKBertolt Kreft
Bertolt Kreft
Immunocytokines (IC) provide the opportunity for targeted delivery of cytokines as payloads to tissues and cells to improve safety and efficacy of cytokine-based therapies. ICs have gained significant interest in recent years and several antibody-cytokine fusion proteins have entered clinical trials. Compared to recombinant fusion proteins, we have developed an entirely different approach to IC generation based on the site-specific, chemical conjugation of synthetic cytokines to antibodies. Bright Peak generates enhanced and conjugatable cytokines using a novel protein engineering platform based on solid-phase peptide synthesis and subsequent chemical ligation of protein segments. Our synthetic cytokines can then be readily chemically conjugated to specific lysine residues in the Fc region of an existing IgG1, IgG2 or IgG4 antibody without the need for prior antibody engineering. Chemical conjugation of cytokine payloads is rapid, enabling the flexible generation of ICs based on different antibodies and payloads within weeks. We applied our technology to more than 10 antibodies and found that neither antigen binding nor payload potency and selectivity are affected by chemical conjugation. Importantly, binding of the Fc domain of ICs to Fc gamma receptors or FcRn is not significantly affected. We are initially focusing on the development of PD-1-targeted ICs to achieve dual-targeting of PD-1+ effector T cells (cis-signaling). Using several anti-PD-1 antibodies and various synthetic IL-2 variants as payloads, we created ICs with different drug-antibody ratios and explored alternative conjugation sites within the Fc region. Resulting PD-1/IL-2 ICs are highly active showing significantly enhanced potency due to avidity resulting from binding of the cytokine to PD-1+ effector T cells in cis. Our PD-1/IL-2 ICs induce strong pharmacodynamic effects in vivo, and we are currently optimizing the pharmacological profiles of PD-1-targeted ICs for clinical application. In addition, we are actively exploring cis-signaling ICs targeting different surface receptors and immune cells. Citation Format: Jean-Philippe Carralot, Matilde Arévalo Ruiz, Robert Tam, Eric Armentani, Vijaya R. Pattabiraman, Bertolt Kreft. Cis-activation of PD-1+ effector T cells with dual-targeting immunocytokines generated using a novel chemical conjugation platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4223.